Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

naxitamab-gqgk

View Patient Information
A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-Gd2 IGG3 monoclonal antibody 3f8 humanized
hu3F8
humanized anti-GD2 antibody 3F8
humanized monoclonal antibody Hu3f8-IGG1
naxitamab
US brand name:Danyelza
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search